SCHEMBL22290720

SCHEMBL22290720

CC(NC(=O)c1ccn(S(C)(=O)=O)c1)C(=O)Nc1nc(-c2cccc(-c3ccncc3)c2)cs1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 3/20 0.64
▸ SMARCA4 P51532 3/20 0.64
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ SLC6A2 P23975 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.46
▸ PARP1 P09874 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ ROCK1 Q13464 11/20 0.42
▸ ROCK2 O75116 10/20 0.42
▸ SGK1 O00141 1/20 0.42
▸ AKT1 P31749 1/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ LIMK1 P53667 1/20 0.42
▸ TNK2 Q07912 1/20 0.42
▸ DMPK Q09013 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290717 1.00 SMARCA2 (0.64) SMARCA2SMARCA4CYP3A4CYP2C9SMN1; SMN2
SCHEMBL22290565 0.92 SMARCA2 (0.62) SMARCA2SMARCA4CYP3A4CYP2C9SMN1; SMN2
SCHEMBL22290564 0.92 SMARCA2 (0.62) SMARCA2SMARCA4CYP3A4CYP2C9SMN1; SMN2
SCHEMBL22290542 0.90 SMARCA2 (0.67) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290540 0.90 SMARCA2 (0.67) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290758 0.90 SMARCA2 (0.69) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290759 0.90 SMARCA2 (0.69) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290494 0.89 SMARCA2 (0.61) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290496 0.89 SMARCA2 (0.61) SMARCA2SMARCA4CYP3A4CYP2C9PARP1
SCHEMBL22290408 0.89 SMARCA2 (0.67) SMARCA2SMARCA4CYP3A4CYP2C9PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SMARCA2 14/4885SMARCA4 6/4885CYP3A4 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback